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Abstract 
Background: The emerging role of TLR2/4 as immuno-metabolic receptors points to key involvement of TLR/IL-1R/
MyD88 pathway in obesity/type-2 diabetes (T2D). IL1R-associated kinase (IRAK)-1 is a critical adapter protein (serine/
threonine kinase) of this signaling pathway. The changes in adipose tissue expression of IRAK-1 in obesity/T2D remain 
unclear. We determined modulations in IRAK-1 gene/protein expression in the subcutaneous adipose tissues from 
lean, overweight and obese individuals with or without T2D.
Methods: A total of 49 non-diabetic (22 obese, 19 overweight and 8 lean) and 42 T2D (31 obese, 9 overweight and 
2 lean) adipose tissue samples were obtained by abdominal subcutaneous fat pad biopsy and IRAK-1 expression was 
determined using real-time RT-PCR, immunohistochemistry, and confocal microscopy. IRAK-1 mRNA expression was 
compared with adipose tissue proinflammatory mediators (TNF-α, IL-6, IL-18), macrophage markers (CD68, CD11c, 
CD163), and plasma markers (CCL-5, C-reactive protein, adiponectin, and triglycerides). The data were analyzed using t 
test, Pearson’s correlation, and multiple stepwise linear regression test.
Results: In non-diabetics, IRAK-1 gene expression was elevated in obese (P = 0.01) and overweight (P = 0.04) as 
compared with lean individuals and this increase correlated with body mass index (r = 0.45; P = 0.001) and fat per-
centage (r = 0.36; P = 0.01). In diabetics, IRAK-1 mRNA expression was also higher in obese as compared with lean 
subjects (P = 0.012). As also shown by immunohistochemistry/confocal microscopy in non-diabetics and by immuno-
histochemistry in diabetics, IRAK-1 protein expression was higher in obese than overweight and lean adipose tissues. 
IRAK-1 gene expression correlated positively/significantly with mRNAs of TNF-α (r = 0.46; P = 0.0008), IL-6 (r = 0.30; 
P = 0.03) and IL-18 (r = 0.31; P = 0.028) in non-diabetics; and only with TNF-α (r = 0.32; P = 0.03) in diabetics. IRAK-1 
expression also correlated positively/significantly with CD68 (r = 0.32; P = 0.02), CD11c (r = 0.30; P = 0.03), and CD163 
(r = 0.43; P = 0.001) in non-diabetics; and only with CD163 (r = 0.34; P = 0.02) in diabetics. IRAK-1 mRNA levels also 
correlated with plasma markers including CCL-5 (r = 0.39; P = 0.02), C-reactive protein (r = 0.48; P = 0.005), adiponec-
tin (r = −0.36; P = 0.04), and triglycerides (r = 0.40; P = 0.02) in non-diabetics; and only with triglycerides (r = −0.36; 
P = 0.04) in diabetics. IRAK-1 expression related with TLR2 (r = 0.39; P = 0.007) and MyD88 (r = 0.36; P = 0.01) in non-
diabetics; and MyD88 (r = 0.52; P = 0.0003) in diabetics.
Conclusions: The elevated IRAK-1 expression in obese adipose tissue showed consensus with local/circulatory 
inflammatory signatures and represented as a tissue marker for metabolic inflammation. The data have clinical signifi-
cance as interventions causing IRAK-1 suppression may alleviate meta-inflammation in obesity/T2D.
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Background
Modern lifestyle has led to the reduced physical activity 
and increased consumption of energy-rich foods which 
are the root cause of the substantial increase in obesity 
worldwide. Obesity is known to induce a state of chronic 
low-grade systemic inflammation in both humans and 
rodents in which the expanded adipose tissue functions as 
an active endocrine organ and secretes adipokines includ-
ing proinflammatory cytokines/chemokines, hormones, 
and other mediators [1–4]. Toll-like receptors (TLRs) are 
the membrane-spanning non-catalytic innate immune 
receptors that recognize pathogen-associated molecular 
patterns (PAMPs) and induce inflammatory responses. 
Free fatty acids, in addition to PAMPs, also act as TLR 
agonists [5] which points to the emerging role of TLRs as 
immunometabolic receptors in obesity. Interleukin (IL)-1 
receptor-associated kinases (IRAKs) are the death domain 
containing serine/threonine kinases and adapter proteins 
that play a crucial role in signaling cascades of IL-1 family 
receptors and TLRs. TLR signaling is initiated in the intra-
cellular toll/IL-1 receptor (TIR) domain and is classified 
into myeloid differentiation factor 88 (MyD88)-depend-
ent or MyD88-independent (TRIF-dependent) pathways 
[6, 7]. The MyD88-dependent signaling is induced by 
TLR dimerization after the TLR engagement with cog-
nate ligands, and results in the recruitment of MyD88 
and IRAKs to the TIR domain [8, 9]. IRAK-1 is activated 
after phosphorylation by IRAK-4 and associates with 
TNF receptor-associated factor (TRAF)-6. The IRAK-1/
TRAF-6 complex further recruits TGFβ-activated kinase 
(TAK)-1 and TAB-1/2 adapter proteins to form a macro-
molecular complex [10]. Hyperphosphorylated IRAK-1 
dissociates from the signaling complex and TAK-1 acti-
vates the inhibitor of nuclear factor kappa (NF-κ)-B 
kinase alpha/beta (IKKα/β) to result in IκBα phospho-
rylation, ubiquitination, degradation, and nuclear trans-
location of p65 NF-κB complexes [11]. Simultaneously, 
TAK-1 phosphorylates members of the mitogen-activated 
protein kinase (MAPK) kinase i.e. MKK family including 
MKK4, MKK3, or MKK6 which, in turn, activate c-Jun 
N-terminal kinase (JNK) and p38 MAPK.
The immunometabolic role of TLR2 and TLR4 makes 
these receptors and their associated pathways critical for 
identifying targets to treat metabolic conditions such as 
obesity-induced inflammation and type-2 diabetes (T2D). 
Obesity leads to the enhanced expression of TLR2 and 
TLR4 on the peripheral blood mononuclear cells which 
has significant implications with regard to inflammation 
[12]. However, it remains unclear how the expression of 
IRAK-1 adapter protein, which is a critical component 
of the TLR/IL-1R/MyD88 pathway, is modulated in obe-
sity or T2D. White adipose tissue is critical with regard 
to obesity and its metabolic complications, including 
T2D, as it is the primary site for energy storage and is 
also an active endocrine organ while the brown adipose 
tissue is related with energy expenditure and regulates 
non-shivering thermogenesis [13]. We hypothesized that 
obesity was an inducer or a positive modulator of IRAK-1 
expression in the human white adipose tissue. Herein, 
we present the data from both non-diabetic and diabetic 
individuals showing higher IRAK-1 gene and protein 
expression in the subcutaneous adipose tissues of obese 
or overweight subjects as compared with lean counter-
parts. The correlations of IRAK-1 gene expression were 
assessed against clinical markers of obesity, local proin-
flammatory mediators, monocyte/macrophage markers, 
systemic inflammatory markers, and more importantly, 




A total of 49 non-diabetic (25 male and 24 female, aged 
26–71 years) and 42 diabetic (24 male and 18 female, aged 
23–72 years) individuals were recruited in the study. The 
participants were classified as lean, overweight, and obese 
based on BMI index. The non-diabetic group comprised 
of 8 lean (BMI = 23.035 ± 2.326 kg/m2; 2 male/6 female), 
19 overweight (BMI =  28.31 ±  1.081  kg/m2; 12 male/7 
female), and 22 obese (BMI = 34.383 ± 2.784 kg/m2; 11 
male/11 female) individuals. The diabetic group com-
prised of 2 lean (BMI = 25.473 ± 0.338 kg/m2; 1 male/1 
female), 9 overweight (BMI =  28.130 ±  1.015  kg/m2; 5 
male/4 female), and 31 obese (BMI = 33.759 ± 2.561 kg/
m2; 18 male/13 female) individuals. Different morbid 
conditions in non-diabetic group included hyperten-
sion (5), hyperlipidemia (2), coronary artery disease (1), 
allergy (1), and asthma (1). In diabetic group, comorbidi-
ties included hypertension (17), hyperlipidemia (5), coro-
nary artery disease (2), allergy (2), and asthma (3). The 
clinico-demographic data of the participants are summa-
rized in Table  1. All participants gave written informed 
consent and the study was approved by the ethics com-
mittee of Dasman Diabetes Institute, Kuwait.
Keywords: Interleukin-1 receptor-associated kinase, Adapter protein, Adipose tissue, Obesity, Type-2 diabetes, 
Metabolic inflammation, Meta-inflammation, TLR/IL-1R/MyD88 pathway
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Anthropometric and physio‑clinical measurements
Anthropometric and physical measurements included 
body weight, height, waist circumference as well as sys-
tolic and diastolic blood pressure. Height and weight 
were measured with barefoot participants wearing light 
indoor clothing using calibrated portable electronic 
weighing scales and portable inflexible height measuring 
bars; the waist circumference at the highest point of the 
iliac crest and the mid-axillary line was measured using 
constant tension tape at the end of a normal expiration 
with arms relaxed at the sides. The whole body composi-
tion including body fat percentage (fat %), soft lean mass 
and total body water were measured using IOI 353 Body 
Composition Analyzer (Jawon Medical, South Korea). 
Blood pressure was measured by using Omron HEM-
907XL digital automatic sphygmomanometer (Omron 
Healthcare Inc. IL, USA). An average of the 3 blood pres-
sure readings, with 5–10  min rest between each, was 
obtained. BMI was calculated using the standard BMI 
formula i.e. body weight (kg)/height (m2).
Regarding clinical laboratory measurements, periph-
eral blood was collected by phlebotomist through 
venipuncture from overnight-fasted (minimum 10  h) 
individuals and the samples were analyzed for fasting 
glucose, glycated hemoglobin (HbA1c), fasting insulin, 
and lipid profile. Glucose and lipid profiles were meas-
ured using Siemens dimension RXL chemistry analyzer 
(Diamond Diagnostics, Holliston, MA, USA). Glycated 
hemoglobin (HbA1c) was measured by using Variant™ 
device (BioRad, Hercules, CA, USA). To determine adi-
pokine levels, blood in EDTA vacutainer tubes was 
centrifuged at 1200×g for 10 min and plasma was col-
lected, aliquoted and stored at −80 °C until use. Plasma 
CCL5 (Intra-assay CV % = 3.6; Inter-assay CV % = 10.3) 
and adiponectin (Intra-assay CV  %  =  3.7; Inter-assay 
CV  %  =  8.5) were assessed using immunobead assays 
(Luminex, Austin, TX, USA) and high sensitivity C-reac-
tive protein (hsCRP) levels were measured using ELISA 
kit (Intra-assay CV % = 4.1; Inter-assay CV % = 6.3) (Bio-
vendor, USA). Plasma triglycerides were measured using 
Table 1 Patients’ characteristics and clinical data
Parameter Non‑diabetic Diabetic
Lean Overweight Obese Lean Overweight Obese
Total number (N) 8 19 22 2 9 31
Male (N) 2 12 11 1 5 18
Female (N) 6 7 11 1 4 13
Age (years) 28–53 29–71 26–66 48–58 45–59 23–72
Body mass index 
(kg/m2)
23.035 ± 2.326 28.31 ± 1.081 34.383 ± 2.784 25.473 ± 0.338 28.130 ± 1.015 33.759 ± 2.561
Fat percentage 
(fat %)
29.757 ± 6.196 32.647 ± 4.998 39.011 ± 4.350 32.100 ± 6.223 33.050 ± 5.379 37.333 ± 5.035
Glucose (mmol/l) 5.096 ± 0.639 5.602 ± 1.559 5.424 ± 0.799 5.800 ± 0.424 8.578 ± 1.770 8.640 ± 2.930
Cholesterol (mmol/l) 5.313 ± 1.254 4.899 ± 0.773 5.233 ± 1.073 5.400 ± 2.546 4.816 ± 1.681 5.065 ± 1.236
High-density lipo-
protein (mmol/l)
1.791 ± 0.477 1.219 ± 0.225 1.115 ± 0.235 1.135 ± 0.148 1.147 ± 0.411 1.129 ± 0.288
Low-density lipopro-
tein (mmol/l)
3.250 ± 1.046 3.147 ± 0.699 3.427 ± 0.942 3.700 ± 2.121 2.767 ± 1.391 3.013 ± 1.106
Triglycerides 
(mmol/l)
0.566 ± 0.216 1.215 ± 0.644 1.465 ± 0.821 1.245 ± 1.252 1.972 ± 0.880 1.913 ± 1.495
HbA1c (%) 5.688 ± 0.464 5.917 ± 1.65 5.863 ± 0.497 6.000 ± 0.283 7.544 ± 1.673 8.235 ± 1.506
Hypertension (N) 0 2 3 0 3 14
Hyperlipidemia (N) 0 0 2 0 2 3
Coronary artery 
disease (N)
0 0 1 0 1 1
Allergy (N) 0 0 1 0 0 2
Asthma (N) 0 1 0 0 0 3
Therapy Nadolol, Lipitor, 
Aspirin
Concor, Lipitor,  
Aspirin, Diovan






cor, Zocor, Mixtard, 
Glucophage, Met-
formin, Capoten
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commercial kit (Intra-assay CV  %  =  0.93; Inter-assay 
CV % = 3.05) (Chema Diagnostica, Monsano, Italy). All 
these assays were carried out following instructions as 
recommended by the manufacturers.
Collection of subcutaneous adipose tissue samples
Human adipose tissue samples (~0.5  g) were collected 
via abdominal subcutaneous fat pad biopsy lateral to 
the umbilicus using standard surgical method. Briefly, 
the periumbilical area was sterilized by alcohol swab-
bing and then locally anesthetized using 2  % lidocaine 
(2 ml). Through a small superficial skin incision (0.5 cm), 
fat tissue was collected. After removal, the biopsy tissue 
was further incised into smaller pieces, rinsed in cold 
phosphate buffered saline (PBS), fixed in 4 % paraform-
aldehyde for 24  h and then embedded in paraffin for 
further use. At the same time, freshly collected adipose 
tissue samples (~50–100  mg) were preserved in RNAl-
ater or embedded in optimal cutting temperature (OCT) 
medium and stored at −80 °C until use.
Real‑time reverse‑transcription polymerase chain reaction 
(RT‑PCR)
Total cellular RNA was purified using RNeasy kit (Qia-
gen, Valencia, CA, USA) as per manufacturer’s instruc-
tions. Briefly, the adipose tissue samples in RNAlater or 
OCT-embedded were thawed and homogenized in Qia-
zol lysis solution (Qiagen, Valencia, CA, USA) using Tis-
sueRuptor (Qiagen, Hildon, Germany) at 33,000 rpm for 
40  s. The homogenate was treated with chloroform and 
separated into aqueous and organic phases by centrifu-
gation at 12,000×g for 15 min at 4  °C. The upper aque-
ous RNA phase was collected, 70 % ethanol was added, 
and the sample was applied to an RNeasy spin column to 
allow total RNA binding with the membrane and to wash 
out phenol and other contaminants. High-quality RNA 
was then eluted in RNase-free water. The quantity of the 
isolated RNA was determined using Epoch™ Spectropho-
tometer System (BioTek, Winooski, USA) and the quality 
was assessed by formaldehyde-agarose gel electropho-
resis. The RNA samples (1 μg each) were reverse tran-
scribed to yield cDNA using random hexamer primers 
and TaqMan reverse transcription reagents (High Capac-
ity cDNA Reverse Transcription kit; Applied Biosystems, 
CA, USA).
For real-time RT-PCR, cDNA (50  ng) was ampli-
fied using TaqMan® Gene Expression MasterMix 
(Applied Biosystems, CA, USA) and gene-specific 20× 
TaqMan Gene Expression Assays as follows: (IRAK-
1) Hs01018347_m1; (TNF-α) Hs01113624_g1; (IL-6) 
Hs00985639_m1; (IL-18) Hs01038788_m1; (CD68) 
Hs02836816_g1; (CD11c) Hs00174217_m1; (CD163) 
Hs00174705_m1; (TLR2) Hs01872448_s1; (TLR4) 
Hs00152939_m1; (MyD88) Hs01573837_g1; and 
(GAPDH) Hs03929097_g1 (Applied Biosystems, CA, 
USA) containing forward and reverse primers and a tar-
get-specific TaqMan® minor groove binder (MGB) probe 
labeled with 6-fluorescein amidite (FAM) dye at the 5′ 
end and non-fluorescent quencher (NFQ)-MGB at the 
3′ end of the probe, for 40 cycles of PCR reaction using 
a 7500 Fast Real-Time PCR System (Applied Biosystems, 
CA, USA). Each cycle consisted of denaturation for 15 s 
at 95  °C, annealing/extension for 1  min at 60  °C which 
started after uracil DNA glycosylase (UDG) activation 
(50 °C for 2 min) and AmpliTaq Gold enzyme activation 
(95 °C for 10 min). The amplified glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) expression was used as 
internal control to normalize the differences in individual 
samples and gene expression level of IRAK-1 relative to 
controls (lean adipose tissue) was calculated using 2−ΔΔCt 
method. Relative mRNA expression was measured as fold 
expression over average of control gene expression. The 
expression level in control samples was assumed as 1 and 
data were presented as mean ± SEM values.
Immunohistochemistry
Paraffin-embedded sections (4  µm thick) of subcutane-
ous adipose tissue were deparaffinized in xylene and 
rehydrated through descending grades of ethanol (100, 
95, and 75 %) to water. Antigen retrieval was performed 
by placing slides in target retrieval solution (pH 6.0; 
Dako, Glostrup, Denmark) in the pressure cooker boil-
ing for 8  min and cooling for 15  min. After washing in 
PBS, endogenous peroxidase activity was blocked with 
3 % H2O2 for 30 min and non-specific antibody binding 
was blocked with 5 % nonfat milk for 1 h followed by 1 % 
bovine serum albumin solution for 1  h. The slides were 
incubated at room temperature overnight with primary 
antibody (1:100 dilution of rabbit polyclonal anti-IRAK 
antibody; Abcam® ab62700). After washing with PBS 
(0.5  % Tween), slides were incubated for 1  h with sec-
ondary antibody (goat anti-rabbit conjugated with horse 
radish peroxidase (HRP) polymer chain; EnVision™ Kit 
from Dako, Glostrup, Denmark) and color was devel-
oped using 3,3ʹ-diaminobenzidine (DAB) chromogen 
substrate. Specimens were washed in running tap water, 
lightly counterstained with Harris hematoxylin, dehy-
drated through ascending grades of ethanol (75, 95, and 
100 %), cleared in xylene, and finally mounted in dibutyl 
phthalate xylene (DPX).
For analysis, digital photomicrographs of the entire adi-
pose tissue sections (20×; Olympus BX51 Microscope, 
Japan) were used to quantify the immunohistochemical 
staining in three different regions to assess the regional 
heterogeneity in tissue samples and the regions were out-
lined using Aperio ImageScope software (Aperio Vista, 
Page 5 of 16Ahmad et al. Diabetol Metab Syndr  (2015) 7:71 
CA, USA). The Aperio-positive pixel count algorithm 
(version 9) was used to quantify the intensity of specific 
staining in the region. The number of positive pixels was 
normalized to the number of total (positive and negative) 
pixels to account for variations in the size of the region 
sampled. Color and intensity thresholds were established 
to detect the immunostaining as positive and back-
ground staining as negative pixels. Once the conditions 
were established, all slides were analyzed using the same 
parameters. The resulting color markup of the analysis 
was confirmed for each slide.
Confocal microscopy
Formalin-fixed and paraffin-embedded sections (8 μm) of 
subcutaneous adipose tissue were processed for immuno-
fluorescent labeling using similar protocol as described for 
immunohistochemistry. After antigen retrieval and block-
ing, the samples were incubated overnight at room tem-
perature with primary antibody (1:100 dilution of rabbit 
polyclonal anti-IRAK antibody) (abcam® ab62700). After 
washing twice with PBS-0.05  % Tween, slides were incu-
bated for 1 h with secondary antibody (1:1000 dilution of 
goat anti-rabbit antibody conjugated with Alexa Fluor® 488; 
Abcam® ab150077) and washed at least thrice in PBS. The 
samples were counterstained with 4′,6-diamidino-2-phe-
nylindole (DAPI) (Vectashield, Vectorlab, -H1500) and 
mounted with cover slips. For image processing and analy-
sis, confocal images of the adipose tissue were collected 
on inverted Zeiss LSM710 Spectral confocal microscope 
(Carl Zeiss, Gottingen, Germany) using EC Plan-Neofluar 
40×/1.30 oil DIC M27 objective lens. Samples were excited 
using a 488  nm diode-pumped solid-state laser and the 
405 nm line of an argon ion laser. After laser excitation of 
the samples, optimized emission detection bandwidths 
were configured by using Zeiss Zen 2010 control software.
Statistical analysis
The data obtained were expressed as mean ±  SEM val-
ues. The group means of IRAK-1 gene expression data, 
after checking for normal distribution, were compared 
using unpaired t-test and the linear dependence between 
two variables was assessed by Pearson’s correlation coef-
ficient ‘r’ values. Mann–Whitney U test was used to com-
pare means of IRAK-1 protein expression data regarding 
lean, overweight and obese adipose tissue samples. SPSS 
Statistics 20 software (IBM Inc. USA) was used to per-
form multiple stepwise linear regression analysis in order 
to determine which variables were independently asso-
ciated as predictors with IRAK-1. GraphPad Prism soft-
ware (version 6.05; San Diego, CA, USA) was used for 
statistical analysis and graphical representation of the 
data. All P-values ≤0.05 were considered statistically 
significant.
Results
Adipose tissue IRAK‑1 expression is significantly elevated 
in obese individuals with or without T2D
IRAK-1 is a key mediator of the TLR/IL-1R signal-
ing cascade. We asked whether obesity modulated 
the expression of IRAK-1 in the adipose tissue. To this 
end, we found that in non-diabetic individuals, IRAK-1 
gene expression in the adipose tissue was significantly 
elevated in obese (P = 0.01) and overweight (P = 0.04) 
individuals as compared with lean subjects (Fig.  1a). 
This increase in the IRAK-1 gene expression correlated 
positively with clinical indicators of obesity such as 
BMI (r = 0.45; P = 0.001) (Fig. 1b) and fat % (r = 0.36; 
P = 0.01) (Fig. 1c). In diabetic patients, IRAK-1 mRNA 
expression in the adipose tissue was also signifi-
cantly higher in obese as compared with lean patients 
(P = 0.012) (Fig. 1d); however, IRAK-1 gene expression 
did not correlate with BMI (r = 0.12; P = 0.46) and fat % 
(r = 0.18; P = 0.26) (Fig. 1e, f ).
IRAK-1 protein expression in non-diabetics was also 
found to be enhanced in the adipose tissue of obese and 
overweight individuals as compared with lean subjects 
as shown by both immunohistochemistry (Fig.  2a–c) 
and confocal microscopy (Fig. 2d–f). Comparison of the 
immunohistochemistry data (5 individuals per group) of 
specific staining intensity quantification using Aperio-
positive pixel count algorithm showed that the IRAK-1 
protein expression was significantly higher in obese as 
compared with lean individuals (P =  0.037) (Additional 
file  1: Figure S1). The tabulated data (Additional file  2: 
Figure S2) compare the gene and protein expression in 
this patient cohort. In diabetics, IRAK-1 protein expres-
sion in the adipose tissue was also significantly higher in 
obese and overweight individuals as compared with lean 
subjects as shown by immunohistochemistry (Fig. 2g–i).
Increased adipose tissue expression of IRAK‑1 mRNA is 
concordant with local expression of proinflammatory 
mediators
Tumor necrosis factor (TNF)-α, IL-6, and IL-18 are the 
signature proinflammatory cytokines. We next investi-
gated whether the IRAK-1 gene expression in the adipose 
tissue of non-diabetic or diabetic individuals was con-
cordant with local expression of representative inflam-
matory mediators or markers. To this effect, we found 
that IRAK-1 mRNA expression in non-diabetics cor-
related positively/significantly with the expression of 
TNF-α (r =  0.46, P =  0.0008) (Fig.  3a), IL-6 (r =  0.30, 
P  =  0.03) (Fig.  3b), and IL-18 (r  =  0.31, P  =  0.028) 
(Fig.  3c). Multiple stepwise linear regression analysis 
showed that TNF-α (P  <  0.0001) and IL-18 (P =  0.025) 
were independent predictors of the adipose tissue inflam-
matory marker IRAK-1. However, in diabetic population, 
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the adipose tissue IRAK-1 gene expression correlated sig-
nificantly only with TNF-α (r = 0.32, P = 0.03) (Fig. 3d) 
and did not correlate with IL-6 (r = 0.18, P = 0.24) and 
IL-18 (r = 0.17, P = 0.29) (Fig. 3e, f, respectively).
Enhanced IRAK‑1 gene expression correlates with adipose 
tissue infiltration by monocytes/macrophages
Macrophages are the key mediators of obesity-associated 
chronic low-grade metabolic inflammation, also called 
meta-inflammation. We next asked whether the increased 
IRAK-1 mRNA expression in the obese adipose tissue of 
non-diabetic and diabetic individuals was supported by 
monocyte/macrophage infiltration in this compartment. 
To this line of investigation, we found that the increased 
IRAK-1 mRNA expression in non-diabetic obese indi-
viduals correlated positively with the expression of CD68 
(r = 0.32, P = 0.02) (Fig. 4a), CD11c (r = 0.30, P = 0.03) 
(Fig.  4b), and CD163 (r =  0.43, P =  0.001) (Fig.  4c). In 
diabetics, IRAK-1 gene expression did not associate with 
CD68 (r = 0.10, P = 0.50) and CD11c (r = 0.25, P = 0.10) 
(Fig.  4d, e, respectively); but it correlated significantly 
with CD163 marker (r = 0.34, P = 0.02) (Fig. 4f ).
Fig. 1 Adipose tissue IRAK-1 gene expression is significantly upregulated in obese non-diabetic/diabetic individuals. IL-1 receptor-associated kinase 
(IRAK)-1 gene expression in the subcutaneous adipose tissue biopsy samples collected from 49 non-diabetic (22 obese, 19 overweight, and 8 lean) 
and 42 type-2 diabetic (T2D) (31 obese, 9 overweight, and 2 lean) individuals was determined by real-time RT-PCR as described in “Patients and 
methods”. a IRAK-1 mRNA expression in non-diabetics was found to be significantly elevated in the adipose tissues of obese (P = 0.01) or over-
weight individuals (P = 0.04) as compared with lean counterparts. The increased IRAK-1 gene expression correlated positively with b body mass 
index (BMI) (r = 0.45; P = 0.001) and c body fat percentage (fat %) (r = 0.36; P = 0.01). d IRAK-1 mRNA expression in T2D patients was also found 
to be significantly elevated in the adipose tissues of obese (P = 0.012) as compared with lean subjects. However, IRAK-1 gene expression did not 
correlate with e BMI (r = 0.12; P = 0.46) and f fat % (r = 0.18; P = 0.26). Due to missing fat % data in non-diabetics and diabetics, 3 each, respective 
individuals had to be eliminated from IRAK-1 correlation analysis with fat %
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Fig. 2 IRAK-1 adipose tissue protein expression is also higher in non-diabetic or diabetic obese individuals. The IRAK-1 protein expression in the 
subcutaneous adipose tissues of 5 non-diabetic individuals was detected by immunohistochemistry/immunofluorescent staining, and in 3 diabetic 
individuals by immunohistochemistry as described in “Patients and methods”. The representative photomicrographs show higher IRAK-1 expression 
(arrows) in the adipose tissues of obese non-diabetic individuals using a–c immunohistochemistry (×100 magnification) and d–f immunofluo-
rescent staining (×40 magnification). The higher IRAK-1 adipose tissue expression (arrows) in obese diabetic individuals is shown (g–i) by using 
immunohistochemistry (×100 magnification)
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Adipose tissue IRAK‑1 mRNA expression correlates 
with systemic inflammatory or obesity clinical markers
Plasma CCL-5 (also called regulated on activation, nor-
mal T cell expressed and secreted or RANTES), and 
CRP are typical markers of systemic inflammation while 
the increased triglyceride levels are clinical indicator of 
obesity. We next assessed whether the obesity-associ-
ated changes in the adipose tissue expression of IRAK-1 
mRNA resonated with plasma levels of these markers. 
To this end, we found that the adipose tissue expres-
sion of IRAK-1 mRNA in non-diabetics correlated with 
plasma levels of CCL-5 (r = 0.39, P = 0.02) (Fig. 5a), CRP 
(r =  0.48, P =  0.005) (Fig.  5b), adiponectin (r = −0.36, 
P = 0.04) (Fig. 5c), and triglycerides (r = 0.40, P = 0.02) 
(Fig.  5d). In diabetic patients, IRAK-1 mRNA expres-
sion did not associate with CCL-5 (r = −0.31, P = 0.09) 
(Fig. 5e), CRP (r = 0.33, P = 0.07) (Fig. 5f ), and adiponec-
tin (r = 0.01, P = 0.9) (Fig. 5g); however, it correlated sig-
nificantly with triglyceride levels (r = −0.36, P =  0.04) 
(Fig. 5h).
IRAK‑1 gene expression in the adipose tissue correlates 
with TLR2 and/or MyD88 gene expression
We next asked if the elevated IRAK-1 mRNA expres-
sion in the obese adipose tissue was related with sign-
aling molecules located upstream in the TLR/IL-1R/
MyD88 cascade. To this effect, we found that in non-
diabetic individuals, IRAK-1 gene expression correlated 
Fig. 3 IRAK-1 mRNA expression is concordant with adipose tissue expression of proinflammatory mediators. The adipose tissue gene expression of 
IRAK-1 and representative proinflammatory mediators such as TNF-α, IL-6, and IL-18 was determined in 49 non-diabetic and 42 diabetic individuals 
by using real-time RT-PCR as described in “Patients and methods”. The data show that IRAK-1 gene expression in non-diabetic individuals correlated 
positively/significantly with a TNF-α (r = 0.46, P = 0.0008); b IL-6 (r = 0.30, P = 0.03); and c IL-18 (r = 0.31, P = 0.028). IRAK-1 gene expression in 
diabetic patients correlated positively/significantly with d TNF-α (r = 0.32, P = 0.03), while it did not correlate with e IL-6 (r = 0.18, P = 0.24) and f 
IL-18 (r = 0.17, P = 0.29)
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positively/significantly with TLR2 (r =  0.39, P =  0.007) 
and MyD88 expression (r = 0.36, P = 0.01) and did not 
associate with TLR4 (r  =  −0.04, P  =  0.76) (Fig.  6a–c). 
However, in diabetic individuals, IRAK-1 gene expres-
sion correlated significantly only with MyD88 expression 
(r = 0.52, P = 0.0003) and had no association with TLR2 
(r  =  0.19, P  =  0.20) and TLR4 (r  =  −0.06, P  =  0.60) 
expression (Fig. 6d–f).
Discussion
IRAK-1 is a critical adapter protein of the TLR/IL-1R/
MyD88 signaling pathway and obesity-associated 
changes in its expression remain unclear. In the present 
study, we have identified IRAK-1 as a tissue marker of 
meta-inflammation in obesity by using gene expression 
analysis in the subcutaneous adipose tissue. IRAK-1 is an 
IL-1R-associated serine/threonine kinase and MyD88 is 
a proximal adapter protein that facilitates IRAK4-medi-
ated phosphorylation of IRAK-1. As a key component of 
the TLR/IL-1R/MyD88 signaling pathway, IRAK-1 is an 
adapter protein and kinase that regulates the formation 
of the TRAF-6/TAK-1/TAB-1/2 macromolecular sign-
aling complex. Later on, through a series of sequential 
events, the dissociation of hyperphosphorylated IRAK-1 
from the macromolecular complex results in phos-
phorylation, ubiquitination, and degradation of IκB-α, 
leading eventually to the activation and nuclear trans-
location of p65 NF-κB complex [14, 15]. The previous 
studies reported roles of MyD88 and/or IRAK adapter 
proteins in the innate immunity [9, 14–19], inflammation 
Fig. 4 Increased IRAK-1 gene expression correlates with adipose tissue infiltration by monocytes/macrophages. The adipose tissue gene expression 
of IRAK-1 and selective monocytes/macrophage markers including CD68, CD11c, and CD163 was determined in 49 non-diabetic and 42 diabetic 
individuals by using real-time RT-PCR. The data show that IRAK-1 gene expression in non-diabetic individuals correlated positively/significantly 
with a CD68 (r = 0.32, P = 0.02); b CD11c (r = 0.30, P = 0.03); and c CD163 (r = 0.43, P = 0.001). IRAK-1 gene expression in diabetic patients did not 
associate with d CD68 (r = 0.10, P = 0.50) and e CD11c (r = 0.25, P = 0.10); however, it correlated significantly with f CD163 expression (r = 0.34, 
P = 0.02)
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and cancer metastasis [20–23]. In the present study, we 
show that IRAK-1 gene expression was significantly 
elevated in the adipose tissues of obese and overweight 
non-diabetic individuals as compared with lean sub-
jects and the changes correlated with clinical hallmarks 
of obesity including BMI and fat % (Fig. 1a–c). However, 
Fig. 5 Adipose tissue IRAK-1 mRNA levels correlate with systemic inflammatory or obesity clinical markers. In non-diabetic (49) and diabetic (42) 
individuals, IRAK-1 gene expression in the adipose tissue was determined using real-time RT-PCR. Plasma levels of representative systemic inflam-
matory or obesity clinical markers, such as CCL5, C-reactive protein, adiponectin, and triglycerides were determined by using commercial kits and 
following the manufacturers’ instructions as described in “Patients and methods”. The data show that IRAK-1 mRNA expression in non-diabetic 
individuals correlated positively/significantly with plasma levels of a CCL5 (r = 0.39, P = 0.02); b C-reactive protein (r = 0.48, P = 0.005); c adiponec-
tin (r = 0.36, P = 0.04); and d triglycerides (r = 0.40, P = 0.02). The IRAK-1 gene expression in diabetic patients did not associate with plasma levels 
of e CCL5 (r = 0.31, P = 0.09); f C-reactive protein (r = 0.33, P = 0.07); and g adiponectin (r = 0.01, P = 0.90) but it correlated significantly with h 
triglyceride levels (r = −0.36, P = 0.04). Notably, the IRAK-1 correlation data are shown for 32 non-diabetic and 30 diabetic individuals as missing 
plasma data necessitated exclusion of the relevant individuals from correlation analysis
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in the adipose tissue samples from diabetic individuals, 
IRAK-1 gene expression was comparably upregulated in 
both overweight and obese individuals and the difference 
between obese and lean subjects was found to be signifi-
cant; whereas IRAK-1 correlated non-significantly with 
BMI and fat % (Fig. 1d–f). In T2D, redistribution changes 
of lipolysis occur in different adipose regions, leading to 
fatty acid mobilization in the favor of visceral fat depot. 
The metabolic perturbations also impair TLR signaling 
pathways, such as those involving MyD88 and IRAK-
1. The lack of correlation between IRAK-1 and BMI or 
fat  % in diabetic patients may be because this group is 
more heterogeneous with regard to immune-metabolic 
changes (as mentioned above), comorbid factors, and 
T2D therapeutic interventions. The data also show that 
IRAK-1 protein expression was remarkably elevated in 
the obese adipose tissues of both non-diabetic and dia-
betic individuals (Fig. 2a–i).
The white adipose tissue is a site for excessive energy 
storage and is also an active endocrine organ that 
secretes adipokines [24]. We sought to determine how 
the changes in the adipose tissue expression of IRAK-1 
related with local expression of typical proinflammatory 
cytokines. To this end, we found that in non-diabetic 
individuals, the transcript levels of TNF-α, IL-6, and 
IL-18 were significantly upregulated in the adipose tis-
sues from obese and overweight individuals as compared 
with lean counterparts and this inflammatory profile 
Fig. 6 IRAK-1 gene expression in the adipose tissue correlates with TLR2 and/or MyD88 gene expression. The adipose tissue gene expression of 
IRAK-1 and upstream signaling components of the TLR/IL-1R/MyD88 pathway including TLR2, TLR4, and MyD88 was determined in 49 non-diabetic 
and 42 diabetic individuals by using real-time RT-PCR as described in “Patients and methods”. The data show that IRAK-1 gene expression in non-
diabetic individuals correlated positively/significantly with a TLR2 (r = 0.39, P = 0.007) and c MyD88 (r = 0.36, P = 0.01) but did not correlate with 
b TLR4 (r = −0.04, P = 0.76). IRAK-1 gene expression in diabetic patients did not associate with d TLR2 (r = 0.19, P = 0.20) and e TLR4 (r = −0.06, 
P = 0.60); however, it correlated significantly with f MyD88 expression (r = 0.52, P = 0.0003). The IRAK-1 correlation with TLR2 and TLR4 is shown for 
45 non-diabetic individuals, each, as the missing TLR2/4 data necessitated exclusion of the relevant individuals from correlation analysis
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of the obese adipose tissue correlated directly with the 
IRAK-1 gene expression (Fig. 3a–c). However, in diabetic 
patients, only the TNF-α mRNA expression correlated 
significantly with IRAK-1 gene expression in the adipose 
tissue (Fig.  3d–f). Thus, TNF-α correlated with IRAK-1 
gene expression in both non-diabetic and diabetic indi-
viduals. TNF-α and IL-6 are proinflammatory cytokines 
expressed by both adipocytes and macrophages [25, 26]. 
IL-18, also known as IFN-γ-inducing factor, is a proin-
flammatory cytokine expressed by macrophages, adipo-
cytes and other cell types and it has been associated with 
several inflammatory conditions [27, 28]. Our data show-
ing elevated IL-18 gene expression in the adipose tissue 
of obese and overweight individuals are concordant with 
previous studies reporting the increased IL-18 mRNA 
expression in obese adipose tissue [29] or in activated 
adipocytes [30]. Our data represent obesity/T2D-related 
inflammatory changes in the subcutaneous adipose tissue 
which is easily accessible by transcutaneous biopsy for 
clinical studies. Of note, a previous study reported that 
both the subcutaneous and visceral depots represented 
the inflammatory changes related with insulin resistance 
in human obesity [31]. However, others showed that the 
changes including systemic inflammation, atheroscle-
rosis, and metabolic syndrome were more pronounced 
in the visceral as compared with subcutaneous adipose 
tissue [32–34]. In any case, the lack of visceral adipose 
tissue data may be regarded as a limitation of this study 
which is listed as one of caveats at the end of discussion.
Apart from obesity- or T2D-related changes in adi-
pocytes, altered composition of the stromal vascular 
cell fraction can also modulate the inflammatory state 
of adipose tissue. The stromal cell fraction comprises 
of different cell types including preadipocytes, fibro-
blasts, endothelial cells, progenitor cells, nerve cells, and 
importantly, immune effector cells [35]. Macrophages are 
among the most abundant immune cells that are found 
in the stromal cell fraction and have been reported to 
accumulate in the expanded adipose tissue mass in obe-
sity [36–38]. In the advanced stages of obesity, different 
types of stromal immune cells such as T lymphocytes, 
neutrophils, and monocytes/macrophages infiltrate into 
the adipose tissue and trigger the inflammatory changes 
via a crosstalk with parenchymal adipocytes. The adi-
pose tissue infiltration of monocytes/macrophages can 
be assessed by detecting expression of multiple selection 
markers. In line with this, as expected, we found that the 
elevated IRAK-1 gene expression in non-diabetics cor-
related positively with CD68, CD11c, and CD163 mac-
rophage marker expression in the obese adipose tissues 
(Fig. 4a–c); whereas IRAK-1 correlated positively/signifi-
cantly only with CD163 in diabetic patients (Fig.  4d–f). 
CD68 is a 110  kDa transmembrane glycoprotein that is 
highly expressed on human monocytes and tissue mac-
rophages; however, it is also expressed by basophils, 
neutrophils, and lymphoblasts [39]. The CD68 protein 
is a member of the lysosome-associated membrane gly-
coprotein (LAMP) family and scavenger receptor fam-
ily. Rapid recirculation of the CD68 from endosomal/
lysosomal compartments to the plasma membrane allows 
macrophage movements over selectin-expressing cells or 
substrates which plays a key role in homing and phago-
cytic activities of the tissue macrophages. CD11c, also 
known as integrin-αx (ITGAX) or CR4, is a 145–150 kDa 
type-I transmembrane protein that is highly expressed 
on dendritic cells, and is also expressed by monocytes/
macrophages, granulocytes, natural killer (NK) cells, and 
T/B lymphocytes. It plays a role in cell adhesion and is 
considered a monocyte/macrophage activation marker 
[40]. CD163 is a 130  kDa scavenger receptor which is 
exclusively expressed by monocytes/macrophages. It 
is an acute phase-regulated receptor and is involved in 
clearance and endocytosis of hemoglobin-hapatoglobin 
complexes by macrophages [41]. After its shedding dur-
ing inflammatory conditions such as T2D, hepatic cir-
rhosis, rheumatoid arthritis, Hodgkin lymphoma, and 
sepsis; the soluble form (sCD163) can play an anti-
inflammatory role and is considered to be a diagnostic 
marker for macrophage activation [42]. The positive cor-
relation between increased IRAK-1 gene expression and 
these markers in obesity indicates the concordance of 
the activation of TLR/IL-1R/MyD88 pathway and mac-
rophage recruitment or colonization in the adipose tissue 
to induce or sustain inflammation. Similarly, a previous 
study reported an interplay among obesity, inflammation, 
and macrophage chemotaxis in breast adipose tissue [43]. 
Overall, our data point to a concordance of IRAK-1 gene 
expression with the inflammatory mediators and mac-
rophage markers, implying that the increased IRAK-1 
gene expression in the obese adipose tissue represents 
a global inflammatory change in this compartment. The 
link between IRAK-1 expression and obesity-associated 
meta-inflammation is also supported by the relationship 
of IRAK-1 or IRAK-2 with other inflammatory condi-
tions such as lung cancer [44], systemic lupus erythema-
tosus [45], Vogt-Koyanagi-Harada (VKH) disease [46], 
and Alzheimer’s disease [47].
We further found that IRAK-1 gene expression in non-
diabetics correlated with the plasma levels of CCL-5, 
CRP, adiponectin, and triglycerides (Fig. 5a–d); while in 
diabetic patients, IRAK-1 correlated significantly only 
with plasma triglycerides (Fig. 5d–h). CCL-5 or RANTES 
is a C–C motif chemokine which acts as a key regula-
tor of leukocyte migration into the sites of inflamma-
tion [48]. CRP is a hepatokine and a component of the 
acute phase reaction. Elevated CRP circulatory levels 
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were found in inflammatory conditions such as Crohn’s 
disease, inflammatory bowel disease, ulcerative coli-
tis, infections, necrosis, malignancy, sepsis, and severe 
trauma [49–51]. Our data showing higher circulatory lev-
els of CCL-5 and CRP in non-diabetics suggest the pres-
ence of systemic inflammation in obese individuals as 
compared with overweight and lean subjects. CCL-5 and 
CRP expression may be cooperatively linked as a previous 
study reported that CRP induced cellular activation and 
production of CCL-5 in the renal tubular epithelial cells 
in a dose-dependent manner [52]. Adiponectin is a pro-
tein hormone secreted by adipose tissue and it is involved 
in glucose regulation and fatty acid oxidation. The circu-
latory levels of adiponectin were reported to correlate 
inversely with body fat percentage [53]. IRAK-1 gene 
expression that showed a positive relationship with fat % 
in our study, as expected, was found to correlate nega-
tively with the plasma adiponectin levels. On the other 
hand, IRAK-1 gene expression correlated positively with 
plasma triglycerides. Notably, a significant correlation 
between obesity and plasma triglyceridemia has been 
previously reported [54]. However, not all obese individ-
uals are found to be hypertriglyceridemic which implies 
that triglyceride levels may or may not be related to the 
circulating lipoproteins. We found that plasma triglycer-
ides correlated inversely with IRAK-1 gene expression in 
the adipose tissue of diabetic patients. Increased triglyc-
eride levels in obesity were reported as a risk factor for 
cardiovascular disease, independently of the high-density 
lipoprotein cholesterol levels [55] and hypertriglyceri-
demia with low high-density lipoprotein cholesterol was 
described as a key feature of the metabolic syndrome in 
obese individuals [56].
TLRs are important regulators of the innate immune 
system that recognize pathogen- or danger-associated 
molecular patterns and TLR intracellular signaling is 
mediated via adapter proteins such as MyD88 and TRIF. 
Our data show the upregulated gene expression of TLR2 
and MyD88 in the adipose tissue of obese individuals. 
The IRAK-1 gene expression correlated positively/sig-
nificantly with both TLR2 and MyD88 in non-diabetics 
while it correlated with MyD88 in diabetic patients 
(Fig. 6a–f). TLR signaling activates transcription factors 
that increase expression of various inflammatory mark-
ers [57]. Increased TLRs expression has been reported in 
other inflammatory conditions as well, such as asthma, 
inflammatory bowel disease, rheumatoid arthritis, and 
type-1 diabetes [58–61]. The hallmark of diabetes is 
hyperglycemia and several studies showed that hyper-
glycemia could cause increased TLR2/4 expression and 
activity in different cell types [62–64]. We found the 
increased TLR2/MyD88 gene expression in the adipose 
tissue of obese/diabetic individuals which correlated 
with IRAK-1 while no significant changes were observed 
in the TLR4 expression. The free fatty acids found in 
the circulation of obese/diabetic individuals may act as 
TLR2/4 ligands to promote inflammatory signaling [65, 
66]. Thus, it may be speculated that hyperglycemia and 
free fatty acids may play a significant role in inducing and 
activating inflammatory signaling via TLR2/4 pathways. 
Notably, high fat diet fed TLR2−/− mice were found to 
be protected from insulin resistance and β-cell dysfunc-
tion [67]. However, depending on type of ligand binding, 
TLR2 may have both pro- and anti-inflammatory effects 
as TLR2 ligands such as zymosan and lectin-1 resulted in 
the expression of anti-inflammatory TGF-β [68, 69]. Also, 
zymosan treatment was reported to decrease hypergly-
cemia and increase regulatory T cell numbers in non-
obese diabetic severe combined immunodeficiency mice 
[69]. Previously, we reported the increased TLR2/4 and 
MyD88/IRAK-1 expression in the peripheral blood mon-
onuclear cells of type-2 diabetic individuals but we could 
not detect IRAK-1 expression in the adipose tissue of 
this patient cohort by using immunohistochemistry [12]. 
In the present study, we therefore analyzed the IRAK-1 
expression at both gene and protein expression levels by 
using quantitative real time RT-PCR and immunohisto-
chemistry/confocal microscopy, respectively. Notably, 
in the present study, a different anti-IRAK-1 antibody 
(ab62700, Abcam) was used for immunohistochemical 
staining than the antibody (ProSci Incorporated) used 
in previous study. The reactivity of anti-IRAK1 antibod-
ies may vary in immune cells and adipose tissue due to 
either different IRAK1 isoforms present or different tar-
get epitopes recognized by different antibodies.
The present data suggest that the increased IRAK-1 
expression may be an additional biomarker for the adi-
pose tissue inflammatory state in obesity. Nonetheless, 
caution is warranted while interpreting these results as 
our study is limited by a few caveats as follows: (1) the 
data represent obesity/T2D-associated changes in the 
subcutaneous adipose tissue while changes in the vis-
ceral adipose tissue remain unclear; (2) adipose tissue 
samples were not fractionated into adipocytes, mac-
rophages and stromal cells for total RNA isolation and 
thus the qPCR data alone may not be able to assess tar-
get gene expression in a particular cell type; (3) it remains 
to be seen whether the expression of other TLRs, such 
as TLR5, which is expressed on both immune and non-
immune cells and is a receptor for flagellin associates 
with IRAK-1 expression in obesity and/or T2D; and 
(4) mechanistically, it would also be interesting to see 
whether the expression levels of regulatory microRNAs, 
such as miR-146a which is a known negative feedback 
regulator of IRAK-1/TRAF-6 and miR-21 which is a sup-
pressor of TLR2 signaling, are deregulated in obesity 
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or T2D. Therefore, further studies on these aspects will 
be required to validate and extend these preliminary 
findings.
Conclusions
Taken together, our data show that in the subcutane-
ous adipose tissue, IRAK-1 expression was significantly 
upregulated in obese and overweight individuals as com-
pared with lean subjects. Based on consensus with both 
circulatory and local inflammatory signatures, IRAK-1 
expression may be regarded as an additional tissue 
marker for meta-inflammation in obesity. The study has 
clinical significance as the approaches intending IRAK-1 
suppression may improve metabolic complications in 
obesity or T2D.
Abbreviations
IRAKs: interleukin (IL)-1 receptor-associated kinases; TLRs: toll-like receptors; 
PAMPs: pathogen-associated molecular patterns; MyD88: myeloid differen-
tiation factor 88; TRAF: TNF receptor-associated factor; TAK: TGFβ-activated 
kinase; IKKα/β: inhibitor of nuclear factor kappa-B kinase subunits alpha/
beta; NF-κB: nuclear factor kappa-B; MAPK: mitogen-activated protein kinase; 
MKK: MAPK kinase; JNK: c-Jun N-terminal kinase; T2D: Type-2 diabetes; BMI: 
body mass index; Fat %: fat percentage; PBS: phosphate buffered saline; OCT: 
optimal cutting temperature; RT-PCR: reverse-transcription polymerase chain 
reaction; MGB: minor groove binder; FAM: fluorescein amidite; NFQ: non-fluo-
rescent quencher; UDG: uracil DNA glycosylase; DAB: 3,3ʹ-diaminobenzidine; 
DPX: dibutyl phthalate xylene; DAPI: 4′,6-diamidino-2-phenylindole; HRP: 
horse radish peroxidase; TNF: tumor necrosis factor; RANTES: regulated on 
activation, normal T cell expressed and secreted; CRP: C-reactive protein; VKH: 
Vogt-Koyanagi-Harada; LAMP: lysosome-associated membrane glycoprotein; 
ITGAX: integrin-alpha х; NK: natural killer.
Authors’ contributions
RA designed and planned experiments, analyzed/interpreted the data, 
prepared graphs, edited manuscript, and procured research funds; PKS and 
RT performed experiments, collected and analyzed the data; MA helped with 
sample collection; AH drafted, reviewed and edited the manuscript; SS guided 
experimental work, analyzed and interpreted the data, reviewed results and 
wrote the manuscript; and KB guided research study, provided material sup-
port, reviewed and approved the manuscript for submission. All authors read 
and approved the final manuscript.
Additional files
Additional file 1: Figure S1. Comparative IRAK-1 protein expression in 
obese, overweight, and lean individuals. The protein expression of IRAK-1 
in non-diabetic obese, overweight, and lean adipose tissue samples, 5 
each, was determined by using immunohistochemistry as described in 
Patients and Methods. Analysis of the IRAK-1 intensity determined by 
using Aperio positive pixel count algorithm software (version 9) revealed a 
significantly higher expression in obese individuals as compared with lean 
subjects (P=0.0317).
Additional file 2: Figure S2. Comparison of IRAK-1 gene and protein 
expression in the adipose tissue. The gene and protein expression of 
IRAK-1 in non-diabetic obese, overweight, and lean adipose tissue 
samples, 5 each, were determined by using real-time RT-PCR and immu-
nohistochemistry, respectively, as described in Patients and Methods. 
The relative mRNA expression was measured as fold expression over 
average of control gene expression taken as 1. The protein expression was 
measured as intensity which was calculated by using Aperio positive pixel 
count algorithm software (version 9).
Acknowledgements
The authors thank Kuwait Foundation for the Advancement of Sciences for 
financial support. We are also grateful to Eman Al Shawaf from Pancreatic Islet 
Biology and Transplantation Laboratory for help with confocal microscopy, 
Sriraman Devarajan from Tissue Bank Unit for help with regression analysis of 
the data, and colleagues from Biochemistry and Molecular Biology Laboratory 
for help through valuable suggestions and information sharing.
Compliance with ethical guidelines
Competing interests
The authors declare that they have no competing interests.
Received: 25 February 2015   Accepted: 18 August 2015
References
 1. Calder PC, Ahluwalia N, Brouns F, Buetler T, Clement K, Cunningham K, 
et al. Dietary factors and low-grade inflammation in relation to over-
weight and obesity. Br J Nutr. 2011;106(Suppl 3):S5–78.
 2. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between 
insulin resistance, obesity and diabetes. Trends Immunol. 2004;25:4–7.
 3. Khaodhiar L, Ling PR, Blackburn GL, Bistrian BR. Serum levels of interleu-
kin-6 and C-reactive protein correlate with body mass index across the 
broad range of obesity. JPEN J Parenter Enteral Nutr. 2004;28:410–5.
 4. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, 
et al. Visfatin, an adipocytokine with proinflammatory and immunomod-
ulating properties. J Immunol. 2007;178:1748–58.
 5. O’Neill LA. How Toll-like receptors signal: what we know and what we 
don’t know. Curr Opin Immunol. 2006;18:3–9.
 6. Burns K, Martinon F, Esslinger C, Pahl H, Schneider P, Bodmer JL, et al. 
MyD88, an adapter protein involved in interleukin-1 signaling. J Biol 
Chem. 1998;273:12203–9.
 7. Kawai T, Akira S. The role of pattern-recognition receptors in innate 
immunity: update on Toll-like receptors. Nat Immunol. 2010;11:373–84.
 8. Burns K, Clatworthy J, Martin L, Martinon F, Plumpton C, Maschera B, 
et al. Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 
receptor. Nat Cell Biol. 2000;2:346–51.
 9. Huang J, Gao X, Li S, Cao Z. Recruitment of IRAK to the interleukin 1 
receptor complex requires interleukin 1 receptor accessory protein. Proc 
Natl Acad Sci USA. 1997;94:12829–32.
 10. Qian Y, Commane M, Ninomiya-Tsuji J, Matsumoto K, Li X. IRAK-mediated 
translocation of TRAF6 and TAB 2 in the interleukin-1-induced activation 
of NFkappa B. J Biol Chem. 2001;276:41661–7.
 11. Takaesu G, Kishida S, Hiyama A, Yamaguchi K, Shibuya H, Irie K, et al. 
TAB 2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by 
linking TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol Cell. 
2000;5:649–58.
 12. Ahmad R, Al-Mass A, Atizado V, Al-Hubail A, Al-Ghimlas F, Al-Arouj M, et al. 
Elevated expression of the toll like receptors 2 and 4 in obese individu-
als: its significance for obesity-induced inflammation. J Inflamm (Lond). 
2012;9:48.
 13. van der Lans AA, Hoeks J, Brans B, Vijgen GH, Visser MG, Vosselman MJ, 
et al. Cold acclimation recruits human brown fat and increases nonshiver-
ing thermogenesis. J Clin Invest. 2013;123:3395–403.
 14. Kanakaraj P, Schafer PH, Cavender DE, Wu Y, Ngo K, Grealish PF, et al. Inter-
leukin (IL)-1 receptor-associated kinase (IRAK) requirement for optimal 
induction of multiple IL-1 signaling pathways and IL-6 production. J Exp 
Med. 1998;187:2073–9.
 15. Thomas JA, Allen JL, Tsen M, Dubnicoff T, Danao J, Liao XC, et al. Impaired 
cytokine signaling in mice lacking the IL-1 receptor-associated kinase. J 
Immunol. 1999;163:978–84.
 16. Muzio M, Ni J, Feng P, Dixit VM. IRAK (Pelle) family member IRAK-2 and 
MyD88 as proximal mediators of IL-1 signaling. Science. 1997;278:1612–5.
 17. Cao Z, Henzel WJ, Gao X. IRAK. a kinase associated with the interleukin-1 
receptor. Science. 1996;271:1128–31.
 18. Kanakaraj P, Ngo K, Wu Y, Angulo A, Ghazal P, Harris CA, et al. Defec-
tive interleukin (IL)-18-mediated natural killer and T helper cell type 1 
Page 15 of 16Ahmad et al. Diabetol Metab Syndr  (2015) 7:71 
responses in IL-1 receptor-associated kinase (IRAK)-deficient mice. J Exp 
Med. 1999;189:1129–38.
 19. Kawagoe T, Sato S, Matsushita K, Kato H, Matsui K, Kumagai Y, et al. 
Sequential control of Toll-like receptor-dependent responses by IRAK1 
and IRAK2. Nat Immunol. 2008;9:684–91.
 20. Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intes-
tinal tumorigenesis through the adaptor protein MyD88. Science. 
2007;317:124–7.
 21. Cataisson C, Salcedo R, Hakim S, Moffitt BA, Wright L, Yi M, et al. IL-
1R-MyD88 signaling in keratinocyte transformation and carcinogenesis. J 
Exp Med. 2012;209:1689–702.
 22. Ochi A, Nguyen AH, Bedrosian AS, Mushlin HM, Zarbakhsh S, Barilla R, 
et al. MyD88 inhibition amplifies dendritic cell capacity to promote 
pancreatic carcinogenesis via Th2 cells. J Exp Med. 2012;209:1671–87.
 23. Rhyasen GW, Starczynowski DT. IRAK signalling in cancer. Br J Cancer. 
2015;112:232–7.
 24. Wozniak SE, Gee LL, Wachtel MS, Frezza EE. Adipose tissue: the new 
endocrine organ? A review article. Dig Dis Sci. 2009;54:1847–56.
 25. Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S, 
et al. PPARgamma activation primes human monocytes into alterna-
tive M2 macrophages with anti-inflammatory properties. Cell Metab. 
2007;6:137–43.
 26. Koppaka S, Kehlenbrink S, Carey M, Li W, Sanchez E, Lee DE, et al. Reduced 
adipose tissue macrophage content is associated with improved insulin 
sensitivity in thiazolidinedione-treated diabetic humans. Diabetes. 
2013;62:1843–54.
 27. Sutinen EM, Pirttila T, Anderson G, Salminen A, Ojala JO. Pro-inflamma-
tory interleukin-18 increases Alzheimer’s disease-associated amyloid-
beta production in human neuron-like cells. J Neuroinflammation. 
2012;9:199.
 28. Huang HY, Yu HT, Chan SH, Lee CL, Wang HS, Soong YK. Eutopic endome-
trial interleukin-18 system mRNA and protein expression at the level of 
endometrial-myometrial interface in adenomyosis patients. Fertil Steril. 
2010;94:33–9.
 29. Bruun JM, Stallknecht B, Helge JW, Richelsen B. Interleukin-18 in plasma 
and adipose tissue: effects of obesity, insulin resistance, and weight loss. 
Eur J Endocrinol. 2007;157:465–71.
 30. Kobashi C, Asamizu S, Ishiki M, Iwata M, Usui I, Yamazaki K, et al. Inhibi-
tory effect of IL-8 on insulin action in human adipocytes via MAP kinase 
pathway. J Inflamm (Lond). 2009;6:25.
 31. Bigornia SJ, Farb MG, Mott MM, Hess DT, Carmine B, Fiscale A, et al. 
Relation of depot-specific adipose inflammation to insulin resistance in 
human obesity. Nutr Diabetes. 2012;2:e30.
 32. Alexopoulos N, Katritsis D, Raggi P. Visceral adipose tissue as a source 
of inflammation and promoter of atherosclerosis. Atherosclerosis. 
2014;233:104–12.
 33. Ohman MK, Shen Y, Obimba CI, Wright AP, Warnock M, et al. Visceral 
adipose tissue inflammation accelerates atherosclerosis in apolipoprotein 
E-deficient mice. Circulation. 2008;117:798–805.
 34. Samaras K, Botelho NK, Chisholm DJ, Lord RV. Subcutaneous and visceral 
adipose tissue gene expression of serum adipokines that predict type 2 
diabetes. Obesity (Silver Spring). 2010;18:884–9.
 35. Lolmede K, Duffaut C, Zakaroff-Girard A, Bouloumie A. Immune cells 
in adipose tissue: key players in metabolic disorders. Diabetes Metab. 
2011;37:283–90.
 36. Morris DL, Singer K, Lumeng CN. Adipose tissue macrophages: pheno-
typic plasticity and diversity in lean and obese states. Curr Opin Clin Nutr 
Metab Care. 2011;14:341–6.
 37. Sell H, Eckel J. Adipose tissue inflammation: novel insight into the role 
of macrophages and lymphocytes. Curr Opin Clin Nutr Metab Care. 
2010;13:366–70.
 38. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW 
Jr. Obesity is associated with macrophage accumulation in adipose tis-
sue. J Clin Invest. 2003;112:1796–808.
 39. Holness CL, Simmons DL. Molecular cloning of CD68, a human 
macrophage marker related to lysosomal glycoproteins. Blood. 
1993;81:1607–13.
 40. Lecoanet-Henchoz S, Gauchat JF, Aubry JP, Graber P, Life P, Paul-Eugene 
N, et al. CD23 regulates monocyte activation through a novel interaction 
with the adhesion molecules CD11b-CD18 and CD11c-CD18. Immunity. 
1995;3:119–25.
 41. Van den Heuvel MM, Tensen CP, van As JH, Van den Berg TK, Fluitsma 
DM, Dijkstra CD, et al. Regulation of CD 163 on human macrophages: 
cross-linking of CD163 induces signaling and activation. J Leukoc Biol. 
1999;66:858–66.
 42. Buechler C, Ritter M, Orso E, Langmann T, Klucken J, Schmitz G. Regula-
tion of scavenger receptor CD163 expression in human monocytes 
and macrophages by pro- and antiinflammatory stimuli. J Leukoc Biol. 
2000;67:97–103.
 43. Santander AM, Lopez-Ocejo O, Casas O, Agostini T, Sanchez L, Lamas-
Basulto E, et al. Paracrine interactions between adipocytes and tumor 
cells recruit and modify macrophages to the mammary tumor microen-
vironment: the role of obesity and inflammation in breast adipose tissue. 
Cancers (Basel). 2015;7:143–78.
 44. Zhang X, Dang Y, Li P, Rong M, Chen G. Expression of IRAK1 in lung cancer 
tissues and its clinicopathological significance: a microarray study. Int J 
Clin Exp Pathol. 2014;7:8096–104.
 45. Jacob CO, Zhu J, Armstrong DL, Yan M, Han J, Zhou XJ, et al. Identification 
of IRAK1 as a risk gene with critical role in the pathogenesis of systemic 
lupus erythematosus. Proc Natl Acad Sci USA. 2009;106:6256–61.
 46. Sun M, Yang P, Du L, Yang Y, Ye J. The role of interleukin-1 receptor-associ-
ated kinases in Vogt-Koyanagi-Harada disease. PLoS One. 2014;9:e93214.
 47. Cui JG, Li YY, Zhao Y, Bhattacharjee S, Lukiw WJ. Differential regulation 
of interleukin-1 receptor-associated kinase-1 (IRAK-1) and IRAK-2 by 
microRNA-146a and NF-kappaB in stressed human astroglial cells and in 
Alzheimer disease. J Biol Chem. 2010;285:38951–60.
 48. Weitzenfeld P, Ben-Baruch A. The chemokine system, and its CCR5 and 
CXCR4 receptors, as potential targets for personalized therapy in cancer. 
Cancer Lett. 2014;352:36–53.
 49. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, 
interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 
2001;286:327–34.
 50. Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, 
prognosis, and cause of cancer. Crit Rev Clin Lab Sci. 2011;48:155–70.
 51. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer develop-
ment. Mol Cancer Res. 2006;4:221–33.
 52. Baer PC, Gauer S, Wegner B, Schubert R, Geiger H. C-reactive protein 
induced activation of MAP-K and RANTES in human renal distal tubular 
epithelial cells in vitro. Clin Nephrol. 2006;66:177–83.
 53. Ukkola O, Santaniemi M. Adiponectin: a link between excess adiposity 
and associated comorbidities? J Mol Med (Berl). 2002;80:696–702.
 54. Despres JP, Moorjani S, Tremblay A, Ferland M, Lupien PJ, Nadeau A, et al. 
Relation of high plasma triglyceride levels associated with obesity and 
regional adipose tissue distribution to plasma lipoprotein-lipid composi-
tion in premenopausal women. Clin Invest Med. 1989;12:374–80.
 55. Austin MA. Plasma triglyceride as a risk factor for cardiovascular disease. 
Can J Cardiol. 1998;14(Suppl B):14B–7B.
 56. National Cholesterol Education Program. Expert panel on detection and 
treatment of high blood cholesterol in adults: third report of the National 
Cholesterol Education Program (NCEP) expert panel on detection, evalu-
ation, and treatment of high blood cholesterol in adults (Adult Treatment 
Panel III) final report. Circulation. 2002;106:3143–421.
 57. Ospelt C, Gay S. TLRs and chronic inflammation. Int J Biochem Cell Biol. 
2010;42:495–505.
 58. Chun E, Lee SH, Lee SY, Shim EJ, Cho SH, Min KU, et al. Toll-like receptor 
expression on peripheral blood mononuclear cells in asthmatics: implica-
tions for asthma management. J Clin Immunol. 2010;30:459–64.
 59. Himmel ME, Hardenberg G, Piccirillo CA, Steiner TS, Levings MK. The role 
of T-regulatory cells and Toll-like receptors in the pathogenesis of human 
inflammatory bowel disease. Immunology. 2008;125:145–53.
 60. Huang QQ, Pope RM. The role of toll-like receptors in rheumatoid arthritis. 
Curr Rheumatol Rep. 2009;11:357–64.
 61. Devaraj S, Dasu MR, Rockwood J, Winter W, Griffen SC, Jialal I. Increased 
toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients 
with type 1 diabetes: further evidence of a proinflammatory state. J Clin 
Endocrinol Metab. 2008;93:578–83.
 62. Rajamani U, Jialal I. Hyperglycemia induces Toll-like receptor-2 and -4 
expression and activity in human microvascular retinal endothelial cells: 
implications for diabetic retinopathy. J Diabetes Res. 2014;2014:790902.
 63. Kaur H, Chien A, Jialal I. Hyperglycemia induces Toll like receptor 4 
expression and activity in mouse mesangial cells: relevance to diabetic 
nephropathy. Am J Physiol Renal Physiol. 2012;303:F1145–50.
Page 16 of 16Ahmad et al. Diabetol Metab Syndr  (2015) 7:71 
 64. Tencerova M, Kracmerova J, Krauzova E, Malisova L, Kovacova Z, 
Wedellova Z, et al. Experimental hyperglycemia induces an increase of 
monocyte and T-lymphocyte content in adipose tissue of healthy obese 
women. PLoS One. 2015;10:e0122872.
 65. Lee JY, Zhao L, Youn HS, Weatherill AR, Tapping R, Feng L, et al. 
Saturated fatty acid activates but polyunsaturated fatty acid inhibits 
Toll-like receptor 2 dimerized with Toll-like receptor 6 or 1. J Biol Chem. 
2004;279:16971–9.
 66. Deopurkar R, Ghanim H, Friedman J, Abuaysheh S, Sia CL, Mohanty P, 
et al. Differential effects of cream, glucose, and orange juice on inflamma-
tion, endotoxin, and the expression of Toll-like receptor-4 and suppressor 
of cytokine signaling-3. Diabetes Care. 2010;33:991–7.
 67. Ehses JA, Meier DT, Wueest S, Rytka J, Boller S, Wielinga PY, et al. Toll-
like receptor 2-deficient mice are protected from insulin resistance 
and beta cell dysfunction induced by a high-fat diet. Diabetologia. 
2010;53:1795–806.
 68. Kiura K, Kataoka H, Yasuda M, Inoue N, Shibata K. The diacylated lipopep-
tide FSL-1 induces TLR2-mediated Th2 responses. FEMS Immunol Med 
Microbiol. 2006;48:44–55.
 69. Karumuthil-Melethil S, Perez N, Li R, Vasu C. Induction of innate immune 
response through TLR2 and dectin 1 prevents type 1 diabetes. J Immu-
nol. 2008;181:8323–34.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
